ST Renfu: The drug approval application for the sustained-release capsules of methylphenidate hydrochloride by its holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. has been accepted.

ST Renfu Announcement: Recently, Renfu Pharmaceutical Co., Ltd., a holding subsidiary of Yichang Renfu, has received the "Acceptance Notice" of the drug registration and market approval application for the sustained-release capsules of methylphenidate hydrochloride issued by the National Medical Products Administration. Methylphenidate hydrochloride sustained-release capsules are mainly used to treat attention deficit hyperactivity disorder in children aged 6 and above. As of now, Yichang Renfu has accumulated approximately 59 million yuan in research and development investment in this project.